Ensign Investigation Overview
BFA is investigating whether Ensign committed securities fraud by making false and misleading statements to investors regarding the quality of care at its nursing facilities, the sustainability of its growth and profit margins, and its regulatory compliance. Investors may be able to file a class action to potentially recover losses.
If you lost money on your Ensign investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
Why is Ensign being investigated for Securities Fraud?
Ensign is being investigated for securities fraud following significant stock drops. The decline in Ensign’s stock price caused significant losses to investors.
Ensign is a healthcare services company that operates skilled nursing, senior living, and rehabilitative care facilities through a network of affiliated providers. Ensign relies heavily on Medicare and Medicaid reimbursements, making government funding and regulatory compliance central to Ensign’s business model.
BFA is investigating whether Ensign misled investors about the quality of care at its facilities, as well as Ensign’s growth, margins, and regulatory compliance.
Why did Ensign’s Stock Drop?
On June 8, 2026, Hunterbrook Capital published a research report titled “Ensign: The Nursing Home Empire Built on Fatal Neglect” based on a five month investigation that alleged “Ensign’s profits can be traced to providing less care than its patients need – and less care than it is meant to provide based on the tax dollars it receives from the government.” According to Hunterbrook, Ensign padded its profit margin by understaffing its facilities while routing Medicare and Medicaid payments to affiliate entities owned or controlled by Ensign.
This news caused the price of Ensign stock to decline $13.88 per share, or 8.2%, from a closing price of $170.30 per share on June 5, 2026, to $156.42 per share on June 8, 2026.
On June 11, 2026, Muddy Waters Research published a research report titled “Ensign: Deceiving the Government at Estimated ~20% of Facilities” based on interviews with former-employees and site visits by private investigators which alleged that Ensign “rents” required nursing-home administrator licenses from off-site administrators that do not actually oversee its facilities to create the appearance of regulatory compliance. According to Muddy Waters, genuine regulatory compliance would significantly reduce Ensign’s profitability.
On this news, the price of Ensign stock declined $4.52 per share, or 3%, from a closing price of $151.65 per share on June 10, 2026, to $147.13 per share on June 11, 2026.
The Ensign Group, Inc. (ENSG) Stock Chart
Image Caption: NASDAQ online chart showing Ensign’s (ENSG) stock drop following the June 8 and June 11, 2026 news.
How Do I Submit My Information?
If you lost money when Ensign securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Adam McCall
adam@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of the class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
